{"id":2206,"date":"2017-07-06T16:49:53","date_gmt":"2017-07-06T11:19:53","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2206"},"modified":"2021-07-24T12:56:48","modified_gmt":"2021-07-24T07:26:48","slug":"the-business-cocktail-30","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30","title":{"rendered":"Stada\u2019s \u20ac5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal; Trillium hunts for partners; Clementia files for $115M IPO"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69deaa4eea7ae\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69deaa4eea7ae\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30\/#Stadas_E53B_buyout_Sinks_brings_in_new_CEO_and_CFO\" >Stada\u2019s \u20ac5.3B buyout Sinks, brings in new CEO and CFO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30\/#Pfizer_takes_30_cents_and_flees_from_its_failing_Brazilian_generics_venture\" >Pfizer takes 30 cents and flees from its failing Brazilian generics venture<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30\/#GlaxoSmithKline_Exscientia_ink_AI-based_drug_discovery_deal_worth_up_to_42M\" >GlaxoSmithKline, Exscientia ink AI-based drug discovery deal worth up to $42M<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30\/#Biotech_Firm_Trillium_hunts_for_new_partners\" >Biotech Firm Trillium hunts for new partners<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30\/#Clementia_files_for_115M_IPO_to_fund_late-phase_trials_in_ultrarare_genetic_bone_diseases\" >Clementia files for $115M IPO to fund late-phase trials in ultrarare genetic bone diseases<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Stadas_E53B_buyout_Sinks_brings_in_new_CEO_and_CFO\"><\/span>Stada\u2019s \u20ac5.3B buyout Sinks, brings in new CEO and CFO<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">After failing to win the shareholder support needed to complete a \u20ac5.32 billion buyout, Stada is changing key executives. The company announced the resignations of CEO Matthias Wiedenfels and CFO Helmut Kraft following a board meeting on Tuesday and quickly appointed new management. A former Boehringer Ingelheim exec, Engelbert Coster Tjeenk Willink will serve as interim CEO, Stada said on Tuesday. The company tapped Bernhard D\u00fcttmann, who has served as CFO at chemicals firm Lanxess and skin care company Beiersdorf, for its top financial post on an interim basis. The executive changes are the latest in a dramatic run for Stada. After months of buyout talk, Stada agreed in May to a buyout by investment firms Bain and Cinven at \u20ac66 a share. But that proposed deal failed to win enough shareholder support in last week&#8217;s vote.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Pfizer_takes_30_cents_and_flees_from_its_failing_Brazilian_generics_venture\"><\/span>Pfizer takes 30 cents and flees from its failing Brazilian generics venture<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">It wasn\u2019t so long ago that Big Pharma identified Brazil as one of the hottest emerging markets for drugs, an opportunity Pfizer took the lead in pursuing. Part of that effort was a $240 million deal for 40% of the generics maker Laborat\u00f3rio Teuto Brasileiro. But the 2010 joint venture never lived up to expectations, and that $240 million has evaporated. The company has accepted a payment of 1 real\u2014the equivalent of 30 cents\u2014to relinquish its stake to the heirs of Laborat\u00f3rio Teuto\u2019s founder. Pfizer confirmed the deal, first reported by Reuters, via email. &#8220;Since 2010, both companies have worked together to improve access to medicines in Brazil,&#8221; a spokesman for Pfizer said. &#8220;Pfizer arrived at this decision as a result of a desire to focus resources on ensuring the success of its existing portfolio and pipeline.&#8221; The transaction ends a year\u2019s worth of effort by Pfizer to offload the Brazilian generics business. Reports emerged last summer that Pfizer and the heirs of Teuto\u2019s founder, Walterci Melo, had brought in Goldman Sachs Group and Grupo BTG Pactual to look into a sale. Among the names bandied about as potential acquirers were generics giants Teva and Mylan. Some investment banks also reportedly expressed interest, including Advent International.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"GlaxoSmithKline_Exscientia_ink_AI-based_drug_discovery_deal_worth_up_to_42M\"><\/span>GlaxoSmithKline, Exscientia ink AI-based drug discovery deal worth up to $42M<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">GlaxoSmithKline has inked a drug discovery collaboration with Exscientia, which automates drug design with its artificial intelligence-based platform. Under the agreement, Dundee, U.K.-based Exscientia will receive research payments from GSK, which could total up to \u00a333 million ($42.7 million). The pair will use GSK\u2019s pharma know-how and Exscientia\u2019s AI-enabled platform to discover small molecules to treat up to 10 targets chosen by GSK, according to a statement. The disease-related targets will span several therapeutic areas and the pair aims to discover preclinical candidates. Exscientia stands to collect up to $42.7 million in milestone payments if all 10 projects are advanced. Exscientia\u2019s AI-based platform designs new molecules and assesses them for their potency, selectivity, and ability to bind to specific targets. It uses a rapid \u201cdesign-make-test\u201d cycle to quickly alter candidates toward the desired criteria.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Biotech_Firm_Trillium_hunts_for_new_partners\"><\/span>Biotech Firm Trillium hunts for new partners<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Trillium Therapeutics is sharpening its focus and seeking new partners as it looks over its pipeline with an eye to the future. Tiny Toronto-based Trillium has been pursuing CD47, a molecule found on the surface of many tumors that guards against their destruction. The idea is that this scrambles a key immune response that helps guard a range of tumor types by preventing a process called phagocytosis, in which the cancer cells are devoured by a phagocyte. Over a year ago, it kick-started a Phase 1 test in relapsed or refractory hematologic malignancies, but the biotech said it had looked over its early-stage work and would change things up. For one early medication, the brain-penetrant, second-generation, covalent EGFR inhibitor TTI-2341, the biotech said it had benchmarked the drug against two approved EGFR inhibitors in lung cancer, and concluded it \u201cappears to be a viable and competitive drug candidate for the treatment of brain cancers and brain metastases.\u201d<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Clementia_files_for_115M_IPO_to_fund_late-phase_trials_in_ultrarare_genetic_bone_diseases\"><\/span>Clementia files for $115M IPO to fund late-phase trials in ultrarare genetic bone diseases<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Clementia Pharmaceuticals has filed to raise $115 million in an IPO. The Canadian biotech wants the cash to bankroll late-phase trials of an oral retinoic acid receptor gamma agonist it licensed from Roche. Montreal, Canada-based Clementia intends to use the IPO money to take the former Roche drug, palovarotene, through two phase 3 trials in fibrodysplasia ossificans progressiva (FOP). If the data are good, Clementia plans to file for approval and make palovarotene the go-to drug for the 800 people diagnosed with the ultra rare bone formation disease. Patients with FOP suffer from pain, disability, and early death as a result of bones forming in their muscles, tendons and ligaments. C, ementia estimates FOP affects 9,000 people globally. Funded by a $60 million mezzanine round led by New Enterprise Associates, Clementia has tested palovarotene in a 40-patient phase 2 trial. That study failed to deliver statistically significant results but nonetheless emboldened Clementia to move into phase 3. The decision was underpinned by data suggesting palovarotene cut formation of new extraskeletal bone by 50%. In patients who did grow new bone, the mean volumes were around 70% lower than in the placebo group.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stada\u2019s \u20ac5.3B buyout Sinks, brings in new CEO and CFO After failing to win the shareholder support needed to complete a \u20ac5.32 billion buyout, Stada is changing key executives. The company announced the resignations of CEO Matthias Wiedenfels and CFO Helmut Kraft following a board meeting on Tuesday and quickly appointed new management. A former [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2134,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17548,17552,717,731,17550,716,17549,985,355,711,460,712,804,17551],"industry":[17225],"therapeutic_areas":[17238,17234],"class_list":["post-2206","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bone-disease","tag-clementia","tag-collaboration","tag-deals","tag-exscientia","tag-funding","tag-genetic-bone-diseases","tag-glaxosmithkline","tag-licensing","tag-ma","tag-pfizer","tag-pharma-industry","tag-stada","tag-trillium","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Stada\u2019s \u20ac5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal<\/title>\n<meta name=\"description\" content=\"After failing to win the shareholder support needed to complete a \u20ac5.32 billion buyout, Stada is changing key executives. The company....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stada\u2019s \u20ac5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal\" \/>\n<meta property=\"og:description\" content=\"After failing to win the shareholder support needed to complete a \u20ac5.32 billion buyout, Stada is changing key executives. The company....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-06T11:19:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"648\" \/>\n\t<meta property=\"og:image:height\" content=\"269\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Stada\u2019s \u20ac5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal","description":"After failing to win the shareholder support needed to complete a \u20ac5.32 billion buyout, Stada is changing key executives. The company....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30","og_locale":"en_US","og_type":"article","og_title":"Stada\u2019s \u20ac5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal","og_description":"After failing to win the shareholder support needed to complete a \u20ac5.32 billion buyout, Stada is changing key executives. The company....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-07-06T11:19:53+00:00","article_modified_time":"2021-07-24T07:26:48+00:00","og_image":[{"width":648,"height":269,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30","name":"Stada\u2019s \u20ac5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2.jpg","datePublished":"2017-07-06T11:19:53+00:00","dateModified":"2021-07-24T07:26:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"After failing to win the shareholder support needed to complete a \u20ac5.32 billion buyout, Stada is changing key executives. The company....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-30#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2.jpg","width":648,"height":269},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2-300x125.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bone Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Clementia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Collaboration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Deals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Exscientia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Funding<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genetic Bone Diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">licensing<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">M&amp;A<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Stada<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Trillium<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bone Disease<\/span>","<span class=\"advgb-post-tax-term\">Clementia<\/span>","<span class=\"advgb-post-tax-term\">Collaboration<\/span>","<span class=\"advgb-post-tax-term\">Deals<\/span>","<span class=\"advgb-post-tax-term\">Exscientia<\/span>","<span class=\"advgb-post-tax-term\">Funding<\/span>","<span class=\"advgb-post-tax-term\">Genetic Bone Diseases<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">licensing<\/span>","<span class=\"advgb-post-tax-term\">M&amp;A<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">Stada<\/span>","<span class=\"advgb-post-tax-term\">Trillium<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 6, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 6, 2017 4:49 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2206"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2206\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2134"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2206"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2206"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}